Literature DB >> 28764630

Optimising assessment of kidney function when managing localised renal masses.

Robert J Ellis1, Andre Joshi2, Keng L Ng3, Ross S Francis3, Glenda C Gobe3, Simon T Wood3.   

Abstract

Increased early and incidental detection, improved surgical techniques and technological advancement mean that the management of renal mass lesions is constantly evolving. The treatment of choice for renal mass lesions has historically been radical nephrectomy. Partial nephrectomy is now recommended for localised renal masses, owing to favourable renal functional outcomes. Ablative renal surgery confers a significant risk of chronic kidney disease. There are few studies assessing long term outcomes of nephrectomy on renal outcomes, and virtually no studies assessing long term outcomes for less invasive therapies such as ablation. Unless a renal mass is clearly benign on imaging, management decisions will be made with an assumption of malignancy. The content of this review applies to both benign and malignant renal mass lesions. We advocate for improved strategies for kidney function assessment and risk stratification, early targeted referral, and regular screening for chronic kidney disease for all patients after surgery.

Entities:  

Keywords:  Kidney diseases; Renal insufficiency; Urologic neoplasms

Mesh:

Substances:

Year:  2017        PMID: 28764630     DOI: 10.5694/mja17.00161

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  End-Stage Kidney Disease following Surgical Management of Kidney Cancer.

Authors:  Robert J Ellis; Daniel P Edey; Sharon J Del Vecchio; Megan McStea; Scott B Campbell; Carmel M Hawley; David W Johnson; Christudas Morais; Susan J Jordan; Ross S Francis; Simon T Wood; Glenda C Gobe
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-28       Impact factor: 8.237

2.  Association between preoperative hydration status and acute kidney injury in patients managed surgically for kidney tumours.

Authors:  Robert J Ellis; Sharon J Del Vecchio; Benjamin Kalma; Keng Lim Ng; Christudas Morais; Ross S Francis; Glenda C Gobe; Rebekah Ferris; Simon T Wood
Journal:  Int Urol Nephrol       Date:  2018-06-05       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.